ES2260057T3 - Virus oncolitico. - Google Patents
Virus oncolitico.Info
- Publication number
- ES2260057T3 ES2260057T3 ES00965106T ES00965106T ES2260057T3 ES 2260057 T3 ES2260057 T3 ES 2260057T3 ES 00965106 T ES00965106 T ES 00965106T ES 00965106 T ES00965106 T ES 00965106T ES 2260057 T3 ES2260057 T3 ES 2260057T3
- Authority
- ES
- Spain
- Prior art keywords
- virus
- vev
- cells
- sequence
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 147
- 210000004027 cell Anatomy 0.000 claims abstract description 306
- 241000711975 Vesicular stomatitis virus Species 0.000 claims abstract description 284
- 101710089751 Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 claims abstract description 139
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 claims abstract description 131
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 91
- 102000014150 Interferons Human genes 0.000 claims abstract description 90
- 108010050904 Interferons Proteins 0.000 claims abstract description 90
- 229940079322 interferon Drugs 0.000 claims abstract description 88
- 230000000694 effects Effects 0.000 claims abstract description 37
- 230000035899 viability Effects 0.000 claims abstract description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 97
- 108090000623 proteins and genes Proteins 0.000 claims description 59
- 201000001441 melanoma Diseases 0.000 claims description 34
- 201000011510 cancer Diseases 0.000 claims description 24
- 208000032839 leukemia Diseases 0.000 claims description 23
- 239000002299 complementary DNA Substances 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 150000007523 nucleic acids Chemical group 0.000 claims description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 11
- 201000005296 lung carcinoma Diseases 0.000 claims description 11
- 230000002238 attenuated effect Effects 0.000 claims description 10
- 102000006381 STAT1 Transcription Factor Human genes 0.000 claims description 9
- 108010044012 STAT1 Transcription Factor Proteins 0.000 claims description 9
- 206010009944 Colon cancer Diseases 0.000 claims description 8
- 108091006027 G proteins Proteins 0.000 claims description 8
- 102000030782 GTP binding Human genes 0.000 claims description 8
- 108091000058 GTP-Binding Proteins 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 6
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 6
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 5
- 206010039491 Sarcoma Diseases 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 5
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims description 4
- 101710085938 Matrix protein Proteins 0.000 claims description 4
- 101710127721 Membrane protein Proteins 0.000 claims description 4
- 101710141454 Nucleoprotein Proteins 0.000 claims description 4
- 230000002601 intratumoral effect Effects 0.000 claims description 4
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims description 3
- 101710177166 Phosphoprotein Proteins 0.000 claims description 3
- 108010026228 mRNA guanylyltransferase Proteins 0.000 claims description 3
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims description 3
- 201000011519 neuroendocrine tumor Diseases 0.000 claims description 3
- 208000000389 T-cell leukemia Diseases 0.000 claims description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 2
- 230000003394 haemopoietic effect Effects 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 10
- 208000003265 stomatitis Diseases 0.000 claims 6
- 201000005787 hematologic cancer Diseases 0.000 claims 5
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 5
- 208000005925 vesicular stomatitis Diseases 0.000 claims 5
- 101150082239 G gene Proteins 0.000 claims 3
- 101150062031 L gene Proteins 0.000 claims 3
- 101150084044 P gene Proteins 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 238000007912 intraperitoneal administration Methods 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 101710120037 Toxin CcdB Proteins 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 11
- 244000052637 human pathogen Species 0.000 abstract description 4
- 241000709664 Picornaviridae Species 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 description 98
- 241001465754 Metazoa Species 0.000 description 37
- 210000002950 fibroblast Anatomy 0.000 description 37
- 241000699670 Mus sp. Species 0.000 description 34
- 230000012010 growth Effects 0.000 description 31
- 230000003612 virological effect Effects 0.000 description 25
- 230000009385 viral infection Effects 0.000 description 21
- 238000011282 treatment Methods 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 17
- 230000000120 cytopathologic effect Effects 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 239000000047 product Substances 0.000 description 15
- 230000035945 sensitivity Effects 0.000 description 15
- 208000036142 Viral infection Diseases 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 241000282412 Homo Species 0.000 description 13
- 230000035772 mutation Effects 0.000 description 13
- 210000004940 nucleus Anatomy 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- 230000000174 oncolytic effect Effects 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- 201000001514 prostate carcinoma Diseases 0.000 description 11
- 230000004614 tumor growth Effects 0.000 description 11
- 206010060862 Prostate cancer Diseases 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 238000011580 nude mouse model Methods 0.000 description 10
- 230000010076 replication Effects 0.000 description 10
- 101001007415 Homo sapiens LEM domain-containing protein 1 Proteins 0.000 description 9
- 102100028300 LEM domain-containing protein 1 Human genes 0.000 description 9
- 241000699660 Mus musculus Species 0.000 description 9
- 230000034994 death Effects 0.000 description 9
- 231100000517 death Toxicity 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 108010047761 Interferon-alpha Proteins 0.000 description 8
- 102000006992 Interferon-alpha Human genes 0.000 description 8
- 210000001185 bone marrow Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- 230000029812 viral genome replication Effects 0.000 description 8
- 101710128836 Large T antigen Proteins 0.000 description 7
- 206010033128 Ovarian cancer Diseases 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 210000005260 human cell Anatomy 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 229950000038 interferon alfa Drugs 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000004088 simulation Methods 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- 108091000080 Phosphotransferase Proteins 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 102000020233 phosphotransferase Human genes 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 241000701161 unidentified adenovirus Species 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 101000797612 Arabidopsis thaliana Protein MEI2-like 3 Proteins 0.000 description 5
- 241000711404 Avian avulavirus 1 Species 0.000 description 5
- 101000857682 Homo sapiens Runt-related transcription factor 2 Proteins 0.000 description 5
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 5
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 5
- 102100025368 Runt-related transcription factor 2 Human genes 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 230000001640 apoptogenic effect Effects 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 239000013043 chemical agent Substances 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000003068 molecular probe Substances 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 102000016914 ras Proteins Human genes 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 208000005176 Hepatitis C Diseases 0.000 description 4
- 102000004289 Interferon regulatory factor 1 Human genes 0.000 description 4
- 108090000890 Interferon regulatory factor 1 Proteins 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 239000013553 cell monolayer Substances 0.000 description 4
- 238000003501 co-culture Methods 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 210000003953 foreskin Anatomy 0.000 description 4
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000010468 interferon response Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 208000025113 myeloid leukemia Diseases 0.000 description 4
- 244000309459 oncolytic virus Species 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000004565 tumor cell growth Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- 241000710188 Encephalomyocarditis virus Species 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 241000702244 Orthoreovirus Species 0.000 description 3
- 241000702263 Reovirus sp. Species 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000005775 apoptotic pathway Effects 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 210000000245 forearm Anatomy 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 231100000590 oncogenic Toxicity 0.000 description 3
- 230000002246 oncogenic effect Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 231100001274 therapeutic index Toxicity 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 230000005945 translocation Effects 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 102000004121 Annexin A5 Human genes 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 101000797614 Arabidopsis thaliana Protein MEI2-like 5 Proteins 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- 108010080611 Cytosine Deaminase Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 101800001014 Non-structural protein 5A Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 102100034574 P protein Human genes 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 206010035039 Piloerection Diseases 0.000 description 2
- 101150016155 Pml gene Proteins 0.000 description 2
- 102000003926 Ribosomal protein L18 Human genes 0.000 description 2
- 108090000343 Ribosomal protein L18 Proteins 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108091034131 VA RNA Proteins 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000005860 defense response to virus Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 229960002963 ganciclovir Drugs 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000005371 pilomotor reflex Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 108700042226 ras Genes Proteins 0.000 description 2
- 230000036387 respiratory rate Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 1
- 102220643871 39S ribosomal protein L9, mitochondrial_E99Q_mutation Human genes 0.000 description 1
- APRZHQXAAWPYHS-UHFFFAOYSA-N 4-[5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-1,3-thiazol-2-yl)tetrazol-3-ium-2-yl]benzenesulfonate Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=C(OCC(O)=O)C=CC=2)=NN1C1=CC=C(S([O-])(=O)=O)C=C1 APRZHQXAAWPYHS-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 108010024878 Adenovirus E1A Proteins Proteins 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102220605874 Cytosolic arginine sensor for mTORC1 subunit 2_D10A_mutation Human genes 0.000 description 1
- 101100044298 Drosophila melanogaster fand gene Proteins 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
- 102100035549 Eukaryotic translation initiation factor 2 subunit 1 Human genes 0.000 description 1
- 101710151743 Eukaryotic translation initiation factor 2 subunit 1 Proteins 0.000 description 1
- 101150064015 FAS gene Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 241000702620 H-1 parvovirus Species 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 206010019973 Herpes virus infection Diseases 0.000 description 1
- 101000926535 Homo sapiens Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 description 1
- 101001095089 Homo sapiens PML-RARA-regulated adapter molecule 1 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 108091054729 IRF family Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000016854 Interferon Regulatory Factors Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102220506215 Lysophospholipid acyltransferase 5_M51R_mutation Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102100032965 Myomesin-2 Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 101710181008 P protein Proteins 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 102100037019 PML-RARA-regulated adapter molecule 1 Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 108010015724 Prephenate Dehydratase Proteins 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 101150001535 SRC gene Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102220467277 Transcription factor TFIIIB component B'' homolog_S431A_mutation Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000711970 Vesiculovirus Species 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 102000018265 Virus Receptors Human genes 0.000 description 1
- 108010066342 Virus Receptors Proteins 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 102220354213 c.149A>G Human genes 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013000 chemical inhibitor Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 102000010982 eIF-2 Kinase Human genes 0.000 description 1
- 108010037623 eIF-2 Kinase Proteins 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 201000003911 head and neck carcinoma Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006658 host protein synthesis Effects 0.000 description 1
- 102000044003 human EIF2AK2 Human genes 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 108010087904 neutravidin Proteins 0.000 description 1
- 230000006548 oncogenic transformation Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000011932 ovarian sarcoma Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 230000009712 regulation of translation Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102200029723 rs11541017 Human genes 0.000 description 1
- 102200097262 rs199472843 Human genes 0.000 description 1
- 102220040488 rs200677800 Human genes 0.000 description 1
- 102200133898 rs2241493 Human genes 0.000 description 1
- 102200068615 rs281865226 Human genes 0.000 description 1
- 102200021594 rs74315368 Human genes 0.000 description 1
- 102220197765 rs754206331 Human genes 0.000 description 1
- 102220170487 rs886048161 Human genes 0.000 description 1
- 102220246999 rs939722027 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 108700026239 src Genes Proteins 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20251—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20261—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39787399A | 1999-09-17 | 1999-09-17 | |
| US397873 | 1999-09-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2260057T3 true ES2260057T3 (es) | 2006-11-01 |
Family
ID=23573018
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES05025974T Expired - Lifetime ES2320239T3 (es) | 1999-09-17 | 2000-09-18 | Virus oncolitico. |
| ES00965106T Expired - Lifetime ES2260057T3 (es) | 1999-09-17 | 2000-09-18 | Virus oncolitico. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES05025974T Expired - Lifetime ES2320239T3 (es) | 1999-09-17 | 2000-09-18 | Virus oncolitico. |
Country Status (13)
| Country | Link |
|---|---|
| EP (2) | EP1218019B1 (enExample) |
| JP (1) | JP5060694B2 (enExample) |
| CN (1) | CN1289098C (enExample) |
| AT (2) | ATE418341T1 (enExample) |
| AU (1) | AU782402B2 (enExample) |
| CA (1) | CA2386920C (enExample) |
| DE (2) | DE60026554T2 (enExample) |
| ES (2) | ES2320239T3 (enExample) |
| HK (1) | HK1044708B (enExample) |
| IL (2) | IL148621A0 (enExample) |
| MX (1) | MXPA02002772A (enExample) |
| NZ (4) | NZ534306A (enExample) |
| WO (1) | WO2001019380A2 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
| US8491884B2 (en) | 2000-05-03 | 2013-07-23 | Oncolytics Biotech Inc. | Virus clearance of neoplastic cells from mixed cellular compositions |
| US7306902B2 (en) | 2002-06-28 | 2007-12-11 | Oncolyties Biotech Inc. | Oncolytic viruses as phenotyping agents for neoplasms |
| DE60110593T2 (de) | 2000-06-26 | 2006-01-19 | Wellstat Biologics Corp. | Entfernung von zellen mit viren |
| CN1332712C (zh) | 2001-05-11 | 2007-08-22 | 沃尔斯泰特生物制剂公司 | 肿瘤消解病毒疗法 |
| AU2008201293B2 (en) * | 2001-07-11 | 2011-08-18 | University Of Miami | Recombinant VSV for the treatment of tumor cells |
| US20030044386A1 (en) * | 2001-07-11 | 2003-03-06 | Barber Glen N. | Recombinant VSV for the treatment of tumor cells |
| JP2004099584A (ja) | 2002-05-02 | 2004-04-02 | Keio Gijuku | Ｈｓｖを用いた抗腫瘍剤 |
| AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
| US7731974B2 (en) | 2003-03-27 | 2010-06-08 | Ottawa Hospital Research Institute | Mutant vesicular stomatitis viruses and uses thereof |
| ES2319424T3 (es) * | 2003-03-27 | 2009-05-07 | Ottawa Health Research Institute | Virus mutantes de la estomatitis vesivular y sus usos. |
| CA2568772A1 (en) | 2004-06-01 | 2005-12-15 | San Diego State University Foundation | Expression system based on recombinant vesicular stomatitis virus synthesizing t7 rna polymerase |
| JP5054522B2 (ja) | 2004-08-20 | 2012-10-24 | ヴィラリティクス リミテッド | 血液ガンを治療するための方法および組成物 |
| CN101065144B (zh) * | 2004-08-20 | 2012-06-13 | 溶瘤病毒有限公司 | 治疗血液癌症的方法和组合物 |
| US10260049B2 (en) | 2005-08-01 | 2019-04-16 | Virocure, Inc. | Attenuated reovirus |
| US10668119B2 (en) | 2005-08-01 | 2020-06-02 | Virocure, Inc. | Attenuated reovirus |
| EP2064229B1 (en) * | 2006-09-15 | 2015-08-12 | Ottawa Hospital Research Institute | Oncolytic rhabdovirus |
| US10369171B2 (en) | 2007-03-13 | 2019-08-06 | Virocure, Inc. | Attenuated reoviruses for selection of cell populations |
| JP2011507523A (ja) * | 2007-12-21 | 2011-03-10 | ワイス・エルエルシー | 遺伝子改変した弱毒化水疱性口内炎ウイルス、組成物およびその使用方法 |
| EP2349296B1 (en) * | 2008-08-21 | 2017-04-05 | Ottawa Hospital Research Institute | Engineered synergistic oncolytic viral symbiosis |
| DE102008050860A1 (de) * | 2008-10-08 | 2010-04-15 | Dorothee Von Laer | LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren |
| WO2010105347A1 (en) | 2009-03-16 | 2010-09-23 | Mcmaster University | Vaccination methods |
| MX365946B (es) | 2009-12-10 | 2019-06-19 | Turnstone Lp | Rabdovirus oncolitico. |
| US9951117B2 (en) | 2010-09-02 | 2018-04-24 | Mayo Foundation For Medical Education And Research | Vesicular stomatitis viruses |
| ES2545357T3 (es) * | 2010-09-02 | 2015-09-10 | Mayo Foundation For Medical Education And Research | Virus de la estomatitis vesicular |
| WO2012167382A1 (en) | 2011-06-08 | 2012-12-13 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Compositions and methods for glioblastoma treatment |
| ES2698076T3 (es) | 2011-10-07 | 2019-01-30 | Isd Immunotech Aps | Identificación de los dominios inmunosupresores en las proteínas de fusión de los virus de ARN con envoltura |
| CN105658790A (zh) | 2013-02-21 | 2016-06-08 | 东安大略研究所儿童医院有限公司 | 疫苗组合物 |
| ES2877553T3 (es) * | 2013-04-10 | 2021-11-17 | Aarhus Univ University Of Aarhus | Uso de dominios inmunosupresores como medicamentos |
| EP3008176B1 (en) | 2013-06-14 | 2019-08-07 | Turnstone Limited Partnership | Compositions and methods for enhancing virus replication |
| EP2826856B9 (en) * | 2013-07-16 | 2016-05-04 | Sia Latima | Genetically stable oncolytic RNA virus, method of manufacturing and use thereof |
| CA2955414A1 (en) | 2014-07-21 | 2016-01-28 | Novellusdx Ltd. | Methods and systems for determining oncogenic index of patient specific mutations |
| CN105233285B (zh) * | 2015-09-06 | 2018-10-12 | 广州威溶特医药科技有限公司 | Epac直接或间接激动剂与溶瘤病毒的联合应用 |
| CN110636853B (zh) | 2017-05-19 | 2024-10-18 | 佐治亚州立大学研究基金会公司 | 重组溶瘤病毒 |
| US10610583B2 (en) | 2017-08-31 | 2020-04-07 | Regents Of The University Of Minnesota | Methods and compositions for treating glioma and medulloblastoma brain tumors using the zika virus |
| EP4442816A3 (en) | 2017-09-22 | 2025-01-08 | Centre National de la Recherche Scientifique | Mutated glycoprotein of vesicular stomatitis virus |
| CN110499297B (zh) * | 2019-08-29 | 2021-07-09 | 上海市公共卫生临床中心 | 一种新型溶瘤病毒及其制备方法和应用 |
| WO2022033469A1 (zh) * | 2020-08-14 | 2022-02-17 | 上海行深生物科技有限公司 | 重组溶瘤病毒及其构建方法和用途 |
| EP4288140A1 (en) | 2021-02-05 | 2023-12-13 | Iovance Biotherapeutics, Inc. | Adjuvant therapy for cancer |
| JP2024507996A (ja) | 2021-02-26 | 2024-02-21 | ケロニア セラピューティクス， インコーポレイテッド | リンパ球を標的とするレンチウイルスベクター |
| US12269882B1 (en) | 2023-09-25 | 2025-04-08 | Kelonia Therapeutics, Inc. | Antigen binding polypeptides |
| US12403194B2 (en) | 2023-09-25 | 2025-09-02 | Kelonia Therapeutics, Inc. | Compositions for treating cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1118403B (de) | 1960-01-27 | 1961-11-30 | Hoechst Ag | Verfahren zur Gewinnung von antitumorwirksamen Sporen |
| GB1069144A (en) | 1963-07-10 | 1967-05-17 | Merck & Co Inc | Method for the treatment of malignant tumors |
| US4806347A (en) | 1985-12-11 | 1989-02-21 | Schering Corporation | Interferon combinations |
| AU673827B2 (en) * | 1992-03-24 | 1996-11-28 | United Cancer Research Institute | Vaccine containing live virus for therapy of viral diseases and malignancies |
| GB9415320D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | Cancer treatment |
| US7153510B1 (en) * | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
| WO1997026904A1 (en) | 1996-01-25 | 1997-07-31 | Medical Research Council | Treatment of non-neuronal cancer using hsv mutant |
| JP4434478B2 (ja) * | 1997-07-11 | 2010-03-17 | イエール ユニバーシティー | リエンジニアリングされた外被を有するラブドウイルス |
| AU9603898A (en) * | 1997-10-09 | 1999-05-03 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| NZ505312A (en) * | 1997-12-22 | 2003-01-31 | Univ Tennesse Res Corp | Recombinant Vesicular Stomatitis virus comprising a heterologous F protein (Paramyxovirus strain SV5) and CD4 antireceptor protein |
| AU3001799A (en) * | 1998-03-12 | 1999-09-27 | Trustees Of The University Of Pennsylvania, The | Producer cells for replication selective viruses in the treatment of malignancy |
| PT1085904E (pt) * | 1998-06-12 | 2013-03-05 | Sinai School Medicine | Vírus de cadeia negativa atenuados com actividade antagonista do interferão alterada, para utilização como vacinas e produtos farmacêuticos |
| CA2370187C (en) * | 1999-04-15 | 2011-08-02 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
-
2000
- 2000-09-18 ES ES05025974T patent/ES2320239T3/es not_active Expired - Lifetime
- 2000-09-18 CN CNB008158983A patent/CN1289098C/zh not_active Expired - Fee Related
- 2000-09-18 CA CA2386920A patent/CA2386920C/en not_active Expired - Fee Related
- 2000-09-18 DE DE60026554T patent/DE60026554T2/de not_active Expired - Lifetime
- 2000-09-18 AT AT05025974T patent/ATE418341T1/de active
- 2000-09-18 WO PCT/US2000/025510 patent/WO2001019380A2/en not_active Ceased
- 2000-09-18 EP EP00965106A patent/EP1218019B1/en not_active Expired - Lifetime
- 2000-09-18 JP JP2001523012A patent/JP5060694B2/ja not_active Expired - Fee Related
- 2000-09-18 NZ NZ534306A patent/NZ534306A/en not_active IP Right Cessation
- 2000-09-18 HK HK02105578.7A patent/HK1044708B/en not_active IP Right Cessation
- 2000-09-18 ES ES00965106T patent/ES2260057T3/es not_active Expired - Lifetime
- 2000-09-18 NZ NZ523805A patent/NZ523805A/en not_active IP Right Cessation
- 2000-09-18 NZ NZ517573A patent/NZ517573A/en not_active IP Right Cessation
- 2000-09-18 EP EP05025974A patent/EP1716858B9/en not_active Expired - Lifetime
- 2000-09-18 MX MXPA02002772A patent/MXPA02002772A/es active IP Right Grant
- 2000-09-18 NZ NZ534307A patent/NZ534307A/en not_active IP Right Cessation
- 2000-09-18 AU AU75882/00A patent/AU782402B2/en not_active Ceased
- 2000-09-18 IL IL14862100A patent/IL148621A0/xx unknown
- 2000-09-18 AT AT00965106T patent/ATE319460T1/de active
- 2000-09-18 DE DE60041210T patent/DE60041210D1/de not_active Expired - Lifetime
-
2002
- 2002-03-11 IL IL148621A patent/IL148621A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE60026554D1 (de) | 2006-05-04 |
| CN1289098C (zh) | 2006-12-13 |
| EP1716858A2 (en) | 2006-11-02 |
| NZ517573A (en) | 2004-02-27 |
| DE60041210D1 (de) | 2009-02-05 |
| ATE418341T1 (de) | 2009-01-15 |
| WO2001019380A3 (en) | 2001-11-22 |
| EP1716858A3 (en) | 2007-08-15 |
| AU782402B2 (en) | 2005-07-28 |
| EP1218019A2 (en) | 2002-07-03 |
| NZ523805A (en) | 2004-09-24 |
| ATE319460T1 (de) | 2006-03-15 |
| CA2386920A1 (en) | 2001-03-22 |
| NZ534307A (en) | 2005-07-29 |
| CA2386920C (en) | 2012-01-24 |
| JP5060694B2 (ja) | 2012-10-31 |
| HK1044708A1 (en) | 2002-11-01 |
| CN1496268A (zh) | 2004-05-12 |
| IL148621A0 (en) | 2002-09-12 |
| MXPA02002772A (es) | 2004-04-02 |
| NZ534306A (en) | 2005-12-23 |
| IL148621A (en) | 2010-02-17 |
| EP1218019B1 (en) | 2006-03-08 |
| HK1092713A1 (en) | 2007-02-16 |
| AU7588200A (en) | 2001-04-17 |
| WO2001019380A2 (en) | 2001-03-22 |
| HK1044708B (en) | 2006-10-27 |
| EP1716858B1 (en) | 2008-12-24 |
| ES2320239T3 (es) | 2009-05-20 |
| DE60026554T2 (de) | 2006-09-28 |
| JP2004525855A (ja) | 2004-08-26 |
| EP1716858B9 (en) | 2009-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2260057T3 (es) | Virus oncolitico. | |
| US8147822B1 (en) | Oncolytic virus | |
| Hastie et al. | Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer | |
| ES2319424T3 (es) | Virus mutantes de la estomatitis vesivular y sus usos. | |
| ES2292207T3 (es) | Tratamiento de neoplasmas con virus clonales, sensibles al interferon. | |
| ES2315595T3 (es) | Composiciones para tratar cancer con uso de virus. | |
| US11723937B2 (en) | Replication-competent vesicular stomatitis viruses | |
| US20210169956A1 (en) | Increased activity of oncolytic newcastle disease virus | |
| JP2005537802A (ja) | ラブドウイルスの組み換え型変異体及びその使用方法 | |
| Song et al. | Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV (F3aa)-GFP] for peritoneally disseminated gastric cancer | |
| US12311000B2 (en) | Chimeric vesiculoviruses and methods of use | |
| Mani et al. | Study on Genetically Engineered Vesicular Stomatitis Virus for the Application of Treating Malignant Diseases using Gene Therapy | |
| HK1092713B (en) | Oncolytic virus | |
| Nakhaei et al. | Oncolytic virotherapy of cancer with vesicular stomatitis virus | |
| Cary | Assessing an M mutant vesicular stomatitis virus for the treatment of glioblastoma multiforme by determining apoptotic mechanisms and antiviral response | |
| Power | Cell carriers for systemic delivery of oncolytic viruses | |
| Berens | The Bcl-2 family proteins BAX and BAK play important but separate roles in the pathogenesis of reovirus encephalitis | |
| HK1191874B (en) | Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus | |
| HK1149053A (en) | Recombinant newcastle disease virus |